Indivior Reports Q1 2025 Results; Guidance Unchanged
Why we think this is neutral
The Q1 2025 results for Indivior were mixed, with a 6% year-over-year decline in total net revenue, driven by intensified generic competition and funding gaps for the SUBLOCADE product. However, the company maintained its full-year 2025 guidance and expects SUBLOCADE growth to resume in the second half of the year. While there are some near-term headwinds, the overall performance appears to be in line with expectations.
Key Points
- Total net revenue declined 6% year-over-year to $266 million
- SUBLOCADE net revenue decreased modestly due to funding gaps among justice system customers
- Company maintained its full-year 2025 guidance, expecting SUBLOCADE growth to resume in H2
Summary
Indivior PLC reported its Q1 2025 results, with total net revenue declining 6% year-over-year to $266 million. This was primarily driven by intensified generic competition for the SUBOXONE Film product in the U.S. and funding gaps among certain justice system customers for the SUBLOCADE product. However, the company maintained its full-year 2025 guidance, expecting SUBLOCADE growth to resume in the second half of the year.